Famulare Michael, Chang Stewart, Iber Jane, Zhao Kun, Adeniji Johnson A, Bukbuk David, Baba Marycelin, Behrend Matthew, Burns Cara C, Oberste M Steven
Institute for Disease Modeling, Intellectual Ventures Laboratory, Bellevue, Washington, USA
Institute for Disease Modeling, Intellectual Ventures Laboratory, Bellevue, Washington, USA.
J Virol. 2015 Oct 14;90(1):317-31. doi: 10.1128/JVI.01532-15. Print 2016 Jan 1.
To assess the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular evolution in Sabin-like poliovirus isolates from Nigerian acute flaccid paralysis cases obtained from routine surveillance. We employed a novel modeling approach to infer substitution and recombination rates from whole-genome sequences and information about poliovirus infection dynamics and the individual vaccination history. We confirmed observations from a recent vaccine trial that VP1 substitution rates are increased for Sabin-like isolates relative to the rate for the wild type due to increased nonsynonymous substitution rates. We also inferred substitution rates for attenuating nucleotides and confirmed that reversion can occur in days to weeks after vaccination. We combine our observations for Sabin-like virus evolution with the molecular clock for VP1 of circulating wild-type strains to infer that the mean time from the initiating vaccine dose to the earliest detection of circulating vaccine-derived poliovirus (cVDPV) is 300 days for Sabin-like virus type 1, 210 days for Sabin-like virus type 2, and 390 days for Sabin-like virus type 3. Phylogenetic relationships indicated transient local transmission of Sabin-like virus type 3 and, possibly, Sabin-like virus type 1 during periods of low wild polio incidence. Comparison of Sabin-like virus recombinants with known Nigerian vaccine-derived poliovirus recombinants shows that while recombination with non-Sabin enteroviruses is associated with cVDPV, the recombination rates are similar for Sabin isolate-Sabin isolate and Sabin isolate-non-Sabin enterovirus recombination after accounting for the time from dosing to the time of detection. Our study provides a comprehensive picture of the evolutionary dynamics of the oral polio vaccine in the field.
The global polio eradication effort has completed its 26th year. Despite success in eliminating wild poliovirus from most of the world, polio persists in populations where logistical, social, and political factors have not allowed vaccination programs of sustained high quality. One issue of critical importance is eliminating circulating vaccine-derived polioviruses (cVDPVs) that have properties indistinguishable from those of wild poliovirus and can cause paralytic disease. cVDPV emerges due to the genetic instability of the Sabin viruses used in the oral polio vaccine (OPV) in populations that have low levels of immunity to poliovirus. However, the dynamics responsible are incompletely understood because it has historically been difficult to gather and interpret data about evolution of the Sabin viruses used in OPV in regions where cVDPV has occurred. This study is the first to combine whole-genome sequencing of poliovirus isolates collected during routine surveillance with knowledge about the intrahost dynamics of poliovirus to provide quantitative insight into polio vaccine evolution in the field.
为评估减毒活脊髓灰质炎病毒疫苗在人体中的基因回复动态,我们研究了从常规监测获得的尼日利亚急性弛缓性麻痹病例中分离出的类萨宾脊髓灰质炎病毒的分子进化。我们采用了一种新颖的建模方法,从全基因组序列以及有关脊髓灰质炎病毒感染动态和个体疫苗接种史的信息中推断替换率和重组率。我们证实了最近一项疫苗试验的观察结果,即由于非同义替换率增加,类萨宾分离株的VP1替换率相对于野生型有所提高。我们还推断了减毒核苷酸的替换率,并证实接种疫苗后数天至数周内可能发生回复突变。我们将类萨宾病毒进化的观察结果与循环野生型毒株VP1的分子钟相结合,推断出从初始疫苗剂量到最早检测到循环疫苗衍生脊髓灰质炎病毒(cVDPV)的平均时间,对于1型类萨宾病毒为300天,2型类萨宾病毒为210天,3型类萨宾病毒为390天。系统发育关系表明,在野生脊髓灰质炎发病率较低的时期,3型类萨宾病毒以及可能的1型类萨宾病毒存在短暂的局部传播。将类萨宾病毒重组体与已知的尼日利亚疫苗衍生脊髓灰质炎病毒重组体进行比较表明,虽然与非萨宾肠道病毒的重组与cVDPV有关,但在考虑从接种到检测的时间后,萨宾分离株-萨宾分离株和萨宾分离株-非萨宾肠道病毒重组的重组率相似。我们的研究全面描绘了口服脊髓灰质炎疫苗在实际应用中的进化动态。
全球根除脊髓灰质炎行动已进入第26个年头。尽管在世界大部分地区成功消除了野生脊髓灰质炎病毒,但在后勤、社会和政治因素不允许开展持续高质量疫苗接种计划的人群中,脊髓灰质炎仍然存在。一个至关重要的问题是消除循环疫苗衍生脊髓灰质炎病毒(cVDPV),其特性与野生脊髓灰质炎病毒难以区分,可导致麻痹性疾病。cVDPV是由于口服脊髓灰质炎疫苗(OPV)中使用的萨宾病毒在对脊髓灰质炎病毒免疫力较低的人群中具有基因不稳定性而出现。然而,其中的动态过程尚未完全了解,因为历史上一直难以收集和解释在发生cVDPV的地区OPV中使用的萨宾病毒进化的数据。本研究首次将常规监测期间收集的脊髓灰质炎病毒分离株的全基因组测序与脊髓灰质炎病毒的宿主内动态知识相结合,以定量洞察实际应用中脊髓灰质炎疫苗的进化情况。